The global TAM for treatment of diabetes is massive. US equity markets have a lot of experience valuing continuous glucose monitoring (CGM) device makers such as the market leader, Dexcom (NYSE; DXCM);
- The global TAM for CGM device makers is c. US$5bn with cagr c.11%.
- DXCM current mkt value = US$35bn, equating to a revenue multiple of about x35!!!
- The point is, US equity markets go bananas over diabetes treatment innovation due to huge TAM, cagr and IP protection.
For the treatment of DFU's;
- TAM of US$7bn and likely c.10% cagr
- The application of Synpath to DFU's is a sleeping giant under the sp of PNV.
Ann: First Patient enrolled - SynPath Diabetic Foot Ulcer Trial, page-51
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.24 |
Change
-0.020(0.88%) |
Mkt cap ! $1.546B | |||
| Open | High | Low | Value | Volume |
| $2.26 | $2.27 | $2.23 | $2.045M | 909.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 39647 | $2.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.24 | 4080 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.25 |
Change
-0.020 ( 0.46 %) |
||||
| Open | High | Low | Volume | ||
| $2.26 | $2.27 | $2.23 | 216364 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| PNV (ASX) Chart |